These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
219 related articles for article (PubMed ID: 12851770)
41. [Current diagnostics and therapy of the overactive bladder and urge incontinence]. Badawi JK; Langbein S Dtsch Med Wochenschr; 2005 Jun; 130(24):1503-6. PubMed ID: 15942840 [TBL] [Abstract][Full Text] [Related]
42. Correlation between the Overactive Bladder questionnaire (OAB-q) and urodynamic data of Parkinson disease patients affected by neurogenic detrusor overactivity during antimuscarinic treatment. Palleschi G; Pastore AL; Stocchi F; Bova G; Inghilleri M; Sigala S; Carbone A Clin Neuropharmacol; 2006; 29(4):220-9. PubMed ID: 16855424 [TBL] [Abstract][Full Text] [Related]
44. The efficacy and tolerability of tarafenacin, a new muscarinic acetylcholine receptor M3 antagonist in patients with overactive bladder; randomised, double-blind, placebo-controlled phase 2 study. Song M; Kim JH; Lee KS; Lee JZ; Oh SJ; Seo JT; Choi JB; Kim SW; Rhee SJ; Choo MS Int J Clin Pract; 2015 Feb; 69(2):242-50. PubMed ID: 25363415 [TBL] [Abstract][Full Text] [Related]
46. A prospective randomized trial comparing the use of tolterodine or weighted vaginal cones in women with overactive bladder syndrome. Yüce T; Dökmeci F; Çetinkaya ŞE Eur J Obstet Gynecol Reprod Biol; 2016 Feb; 197():91-7. PubMed ID: 26720597 [TBL] [Abstract][Full Text] [Related]
47. The cost-effectiveness of solifenacin vs fesoterodine, oxybutynin immediate-release, propiverine, tolterodine extended-release and tolterodine immediate-release in the treatment of patients with overactive bladder in the UK National Health Service. Cardozo L; Thorpe A; Warner J; Sidhu M BJU Int; 2010 Aug; 106(4):506-14. PubMed ID: 20132203 [TBL] [Abstract][Full Text] [Related]
48. Antimuscarinics and the overactive detrusor--which is the main mechanism of action? Andersson KE; Yoshida M Eur Urol; 2003 Jan; 43(1):1-5. PubMed ID: 12507537 [TBL] [Abstract][Full Text] [Related]
51. Tolterodine extended release improves overactive bladder symptoms in men with overactive bladder and nocturia. Kaplan SA; Roehrborn CG; Dmochowski R; Rovner ES; Wang JT; Guan Z Urology; 2006 Aug; 68(2):328-32. PubMed ID: 16904446 [TBL] [Abstract][Full Text] [Related]
52. In women with urinary incontinence how necessary is cystometry? Saleem A J Pak Med Assoc; 2010 May; 60(5):356-9. PubMed ID: 20527606 [TBL] [Abstract][Full Text] [Related]
53. Editorial comment on: Cizolirtine citrate is safe and effective for treating urinary incontinence secondary to overactive bladder: a phase 2 proof-of-concept study. Costantini E; Lazzeri M Eur Urol; 2010 Jan; 57(1):152-3. PubMed ID: 19446952 [No Abstract] [Full Text] [Related]
54. Editorial comment on: Cizolirtine citrate is safe and effective to treat urinary incontinence secondary to overactive bladder: a phase 2 proof-of-concept study. Soljanik I Eur Urol; 2010 Jan; 57(1):153. PubMed ID: 19446950 [No Abstract] [Full Text] [Related]
55. Solifenacin succinate for the treatment of symptoms of overactive bladder. Maniscalco M; Singh-Franco D; Wolowich WR; Torres-Colón R Clin Ther; 2006 Sep; 28(9):1247-72. PubMed ID: 17062299 [TBL] [Abstract][Full Text] [Related]
56. Treatment of overactive bladder in the aging population: focus on darifenacin. Jha S; Parsons M Clin Interv Aging; 2006; 1(4):309-16. PubMed ID: 18046909 [TBL] [Abstract][Full Text] [Related]
57. A drug safety evaluation of mirabegron in the management of overactive bladder. Robinson D; Thiagamoorthy G; Cardozo L Expert Opin Drug Saf; 2016 May; 15(5):689-96. PubMed ID: 26980445 [TBL] [Abstract][Full Text] [Related]